Randall Hall, MD
Family Medicine · Fairhope, ALNPI 1497739023
Payments from drug & device makers
Across 272 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$449
- AbbVie$431
- Otsuka America Pharmaceutical, Inc.$416
- Novo Nordisk$369
- Pfizer$303
- Merck$199
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,300100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 31 | $449 |
| AbbVie(2 entities) | 34 | $431 |
| Otsuka America Pharmaceutical, Inc. | 19 | $416 |
| Novo Nordisk | 25 | $369 |
| Pfizer | 24 | $303 |
| Merck | 15 | $199 |
| AstraZeneca | 13 | $194 |
| Almatica Pharma LLC | 8 | $181 |
| GSK | 11 | $176 |
| Novartis | 8 | $175 |
| Acadia Pharmaceuticals Inc | 7 | $160 |
| Corium, LLC | 11 | $145 |
| Lilly USA, LLC | 10 | $141 |
| Neos Therapeutics, LP | 6 | $120 |
| Bayer | 6 | $119 |
| Astellas Pharma US Inc | 8 | $115 |
| Exact Sciences | 5 | $94 |
| Avanir Pharmaceuticals, Inc. | 4 | $76 |
| Tris Pharma Inc | 3 | $51 |
| Amgen | 3 | $47 |
| Lundbeck LLC | 2 | $37 |
| Abbott | 2 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Axsome Therapeutics, Inc. | 2 | $30 |
| Shire North American Group Inc | 2 | $30 |
| Supernus Pharmaceuticals, Inc. | 2 | $26 |
| Medtronic | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Tolmar, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Adlon Therapeutics L.p. | 1 | $16 |
| SK Life Science, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Inogen, Inc. | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$4,300 in reported general payments places this provider in the 80th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 51 | $184,109 |
| EliquisApixaban | 499 | $171,197 |
| IngrezzaValbenazine Tosylate | 59 | $115,874 |
| OzempicSemaglutide | 65 | $114,004 |
| MounjaroTirzepatide | 77 | $99,564 |
| JardianceEmpagliflozin | 118 | $82,418 |
| TrulicityDulaglutide | 48 | $71,239 |
| XareltoRivaroxaban | 252 | $69,154 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 74 | $55,397 |
| JanuviaSitagliptin Phosphate | 103 | $47,243 |
| NuplazidPimavanserin Tartrate | 26 | $43,445 |
| FarxigaDapagliflozin Propanediol | 31 | $25,229 |
| LinzessLinaclotide | 36 | $23,652 |
| MyrbetriqMirabegron | 150 | $23,301 |
| NuedextaDextromethorphan Hbr/Quinidine | 58 | $21,976 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $303 | $182,935536 claims |
| Lilly USA, LLCMounjaro, Trulicity | $141 | $170,803125 claims |
| Novo NordiskOzempic | $369 | $114,00465 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $176 | $78,995115 claims |
| Johnson & JohnsonXarelto | $449 | $69,154252 claims |
| MerckJanuvia | $199 | $47,243103 claims |
| Acadia Pharmaceuticals IncNuplazid | $160 | $43,44526 claims |
| AstraZenecaFarxiga | $194 | $25,22931 claims |
| AbbVieLinzess | $431 | $23,65236 claims |
| Astellas Pharma US IncMyrbetriq | $115 | $23,301150 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $76 | $21,97658 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $416 | $17,65727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Fairhope
- Andrew FreemanFairhope$23K
- Amanda RobinsonFairhope$17K
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.